Investigation Questions Drug's Approval for Agitation in AD

The agency defended approval of brexpiprazole (Rexulti) for the treatment of agitation, saying the antipsychotic fills an unmet medical need.
Medscape Medical News

source https://www.medscape.com/viewarticle/995697?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?